One of Tachi's new­ly born lega­cy biotechs rais­es $135M and en­lists an A-list board to ad­vance late-stage vac­cine

Tachi is gone, but his lega­cy biotechs are con­tin­u­ing to make news.

This morn­ing it’s the new­ly born Hill­e­Vax — a cre­ation of Take­da and Fra­zier Health­care Part­ners, where Tachi Ya­ma­da was re­spec­tive­ly CSO and a long­time part­ner — that’s tak­ing a big step for­ward to late-stage test­ing of its norovirus vac­cine with a $135 mil­lion crossover megaraise. Hill­e­Vax CEO Rob Her­sh­berg — who be­came Cel­gene CSO and BD chief af­ter they bought out his ear­li­er start­up, Ven­tiRx — is at the helm. And the start­up crew has at­tract­ed some star tal­ent to the board of what will re­main a rel­a­tive­ly small, close­ly fo­cused biotech team look­ing to take the long, tra­di­tion­al route to a vac­cine ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER